Cipla Limited (CIPLA) — Announcement | 25 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
USFDA issues seven Form 483 observations after Pithampur inspection
💡 Investor Takeaway
This regulatory action may affect investor confidence in Cipla's US market compliance.
⚠️ Risks
Potential regulatory scrutiny impacting manufacturing operations

Cipla announced that the USFDA completed a follow-up cGMP inspection at its Pithampur facility from August 17-25, 2026, issuing seven Form 483 observations. The company will address these observations collaboratively with the FDA within the required timeframe, reaffirming its commitment to manufacturing compliance.

📄 View Original Announcement (PDF)

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹1,14,390.9 Cr P/E: 33.9 ROE: 9.8% ROCE: 13.2% Div Yield: 0.92%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day